So let me talk about a few of the growth opportunities in more detail. But I’ll do that in a balance way. We are also looking the risks and the challenges that we’ve been facing. So if we look at 2011, we had growth drivers of QIAsymphony’s. We have now – are targeting towards the end of the year 550 placements of QIAsymphony, which is a record placement number. I don’t think there has ever been a medium throughput testing system in this industry that sold anywhere close to this type of a ramp-up that we seen here for this noble platform.

Read the rest of this transcript for free on

If you liked this article you might like

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

3 Diversified Services Stocks Nudging The Industry Higher

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Watch Out: Barbarians At The Gate For Qiagen (QGEN)